United States:
Latest Developments In IP Strategies For Pharmaceuticals
13 July 2022
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
To print this article, all you need is to be registered or login on Mondaq.com.
The strategies used to create and maintain strong pharmaceutical
patent portfolios must evolve with developments in the
pharmaceutical space. These developments include not just
scientific advancements but also requirements and practices of
regulatory bodies, such as the United States Food and Drug
Administration (FDA). This article addresses innovative prosecution
strategies and useful considerations
that may facilitate better agreement between pharmaceutical patent
practice and FDA policy.
Read "Latest Developments in IP
Strategies for Pharmaceuticals″
Summer 2022, International Pharmaceutical Industry
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
USPTO Embraces AI Tools In New Guidance
Crowell & Moring LLP
On April 11, 2024, the USPTO published its "Guidance on Use of Artificial Intelligence-Based Tools in Practice Before the United States" in the Federal Register (the "Guidance"). As the title suggests...
Breaking Down The EPO's Revised Practice Guidelines
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
The guidelines for examination in the European Patent Office instruct on the practice and procedure related to the examination of European patent applications...
USPTO Issues Guidance On Use Of AI-Based Tools
Greenberg Traurig, LLP
On April 11, 2024, the U.S. Patent and Trademark Office (USPTO) issued Guidance on Use of Artificial-Intelligence-Based Tools (Guidance), which applies existing rules and policies...